In the last trading session, 3.65 million NLS Pharmaceutics Ltd (NASDAQ:NLSP) shares changed hands as the company’s beta touched -0.52. With the company’s per share price at $2.69 changed hands at -$0.34 or -11.22% during last session, the market valuation stood at $6.65M. NLSP’s last price was a discount, traded about -804.83% off its 52-week high of $24.34. The share price had its 52-week low at $3.00, which suggests the last value was -11.52% down since then. When we look at NLS Pharmaceutics Ltd’s average trading volume, we note the 10-day average is 47300.0 shares, with the 3-month average coming to 215.82K.

Analysts gave the NLS Pharmaceutics Ltd (NLSP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended NLSP as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. NLS Pharmaceutics Ltd’s EPS for the current quarter is expected to be 0.

NLS Pharmaceutics Ltd (NASDAQ:NLSP) trade information

Instantly NLSP was in red as seen at the end of in last trading. With action -24.44%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -88.60%, with the 5-day performance at -24.44% in the red. However, in the 30-day time frame, NLS Pharmaceutics Ltd (NASDAQ:NLSP) is -25.28% down. Looking at the short shares, we see there were 55986.0 shares sold at short interest cover period of 0.11 days.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 7.15%.

NLSP Dividends

NLS Pharmaceutics Ltd is expected to release its next quarterly earnings report in January.

ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 6.0535% or 2.31 million shares worth $0.5 million as of 2024-06-30.